When should low‑dose aspirin (75‑100 mg daily) be recommended for primary and secondary cardiovascular disease prevention?

When to Recommend Aspirin

For secondary prevention (patients with established cardiovascular disease), recommend aspirin 75-162 mg daily indefinitely; for primary prevention, recommend aspirin only in adults aged 40-59 years with ≥10% 10-year CVD risk who have low bleeding risk, are willing to take it for ≥10 years, and have life expectancy ≥10 years—and recommend AGAINST routine aspirin use in adults ≥60 years for primary prevention. 1, 2

Secondary Prevention (Established Cardiovascular Disease)

Aspirin is a Class I recommendation (strongest evidence) for all patients with established atherosclerotic disease 1:

• Coronary artery disease: 75-162 mg daily unless contraindicated
• Post-stroke or TIA: 75-325 mg daily (or clopidogrel 75 mg daily as alternative)
• Peripheral artery disease: 75-325 mg daily (or clopidogrel 75 mg daily)
• Post-CABG: Start within 6 hours after surgery, 100-325 mg daily for 1 year
• Post-PCI with stent: Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for ≥12 months

For secondary prevention, the evidence is unequivocal—aspirin reduces nonfatal MI by 26%, stroke by 25%, and all-cause mortality by 13% 3. The number needed to treat over 33 months is 83 to prevent one cardiovascular event, while the number needed to harm is 111 for one major bleeding event 3.

Primary Prevention (No Known Cardiovascular Disease)

The landscape has shifted dramatically with recent evidence showing bleeding risks often outweigh benefits in lower-risk populations.

Age 40-59 Years with High CVD Risk

Consider aspirin (individualized decision) if ALL criteria met 2:

• 10-year CVD risk ≥10% (calculate using ACC/AHA Pooled Cohort Equations)
• NOT at increased bleeding risk (no history of GI ulcers, recent bleeding, concurrent anticoagulation, thrombocytopenia)
• Life expectancy ≥10 years
• Willing to take daily aspirin for ≥10 years
• Unable to optimally control modifiable ASCVD risk factors despite other interventions 4

The 2022 USPSTF guideline downgraded this from a "B" (moderate recommendation) to a "C" recommendation (selective offering), reflecting that the net benefit is small 2. The absolute benefit is modest: treating 1000 patients prevents approximately 33 cardiovascular events but causes 9 major bleeding events 3.

Age 60 Years and Older

Recommend AGAINST initiating aspirin for primary prevention (Grade D recommendation) 2. The 2022 USPSTF explicitly states there is no net benefit in this age group, representing a major shift from the 2016 guideline that suggested individualized decision-making for ages 60-69 5, 2.

This change reflects three major trials (ARRIVE, ASCEND, ASPREE) published between 2018-2019 showing that bleeding risks consistently outweighed cardiovascular benefits in older adults 4, 6. A 2026 study even suggests long-term aspirin use may increase heart failure risk by 7% 7.

Age Under 40 Years or Over 70 Years

Insufficient evidence to make a recommendation 5, 2. Do not routinely prescribe aspirin in these age groups for primary prevention.

Critical Bleeding Risk Assessment

Before recommending aspirin, explicitly assess for increased bleeding risk:

• History of GI ulcers or GI bleeding
• Recent bleeding from any site
• Concurrent anticoagulation (warfarin, DOACs)
• Concurrent antiplatelet therapy
• Thrombocytopenia or bleeding disorders
• Uncontrolled hypertension (SBP >150 mmHg)
• Chronic kidney disease
• Liver disease
• Age >70 years (inherently higher bleeding risk)

If any bleeding risk factors present, aspirin is generally contraindicated for primary prevention 2.

Dosing

• Primary prevention: 75-100 mg daily 5, 2
• Secondary prevention: 75-162 mg daily (81 mg preferred after PCI) 1
• Higher doses (up to 325 mg) do not provide additional cardiovascular benefit but increase bleeding risk 1

Common Pitfalls

Inappropriate routine use is widespread: A 2022 study found 27.6% of patients receiving aspirin for primary prevention were using it inappropriately (age <40 or >70), and 26% had no recommended indication 8. Another 2024 study found 46-58% of primary prevention aspirin users were taking it contrary to guidelines 9.

Deprescribing is necessary: For patients already on aspirin who no longer meet criteria (especially those ≥60 years or with new bleeding risk factors), actively deprescribe rather than continuing by inertia 10, 9.

Diabetes is NOT an automatic indication: While earlier guidelines suggested aspirin for diabetic patients, recent evidence shows similar risk-benefit profiles as non-diabetic patients—the same age and CVD risk criteria apply 6.

Pregnancy: Avoid aspirin during the last 3 months of pregnancy unless specifically directed by a physician, as it may cause problems in the unborn child or complications during delivery 11.

Practice-Level Variation

There is significant practice-level variation in inappropriate aspirin use (median rate ratio 1.71), with predicted median practice rates ranging from 24.1% to 40.8% 8. This suggests systematic practice-level interventions (clinical decision support, provider education, deprescribing protocols) are needed rather than relying solely on individual clinician judgment.